Hyperuricemia is a condition characterized by elevated uric acid levels in the blood, which can lead to gout and other serious complications. It accounts for a significant global health burden, with prevalence rates ranging from 2.6% to 36% in different populations. Despite the availability of treatments such as allopurinol and febuxostat, there remains a high unmet clinical need for more effective therapies. Current treatments may not adequately control uric acid levels or prevent flare-ups. The growing focus on novel hyperuricemia drug candidates, such as urate-lowering agents and uric acid transport inhibitors, is expected to drive pipeline growth and offer improved outcomes for patients in the coming years.
Major companies involved in the hyperuricemia pipeline drug market include Shenyang Sunshine Pharmaceutical Co., Ltd., Innovent Biologics (Suzhou) Co. Ltd., and others.
Leading drugs currently in the pipeline include HR091506 Tablets, Febuxostat, IG3018, and others.
Increasing demand for more effective treatments and the development of novel drug candidates targeting uric acid reduction are key factors driving the growth of the hyperuricemia pipeline landscape, aiming to address significant unmet clinical needs.
The Hyperuricemia Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into hyperuricemia therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for hyperuricemia. The hyperuricemia report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The hyperuricemia pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with hyperuricemia treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to hyperuricemia.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Hyperuricemia is a condition characterized by an excess of uric acid in the bloodstream. It occurs when the body either produces too much uric acid or fails to excrete enough through the kidneys. This can lead to the formation of urate crystals, causing inflammation and pain, especially in the joints, resulting in conditions like gout.
Hyperuricemia is typically treated with uric acid-lowering medications, such as allopurinol and febuxostat, which reduce uric acid production. Nonsteroidal anti-inflammatory drugs (NSAIDs) and colchicine may be used to manage flare-ups, while lifestyle changes like dietary modification and weight management play a supportive role in controlling the condition.
The global prevalence of hyperuricemia varies significantly, with rates ranging from 2.6% to 36% across different populations. A 2024 study reveals that approximately 21% of adults in the United States, or 43 million individuals, are affected, while in India, the prevalence stands at 44.6%. A 2022 report indicates that in Europe, hyperuricemia affects 19.1% to 25.0% of the population, and in Japan, the prevalence is 26.8% in men and 9% in women.
This section of the report covers the analysis of hyperuricemia drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phases II and III cover a significant share of the total hyperuricemia clinical trials.
The drug molecule categories covered under the hyperuricemia pipeline analysis include small molecules, monoclonal antibodies, gene therapies, and enzyme replacement therapies. The hyperuricemia report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for hyperuricemia.
The EMR report for the hyperuricemia drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed hyperuricemia therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in hyperuricemia clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for hyperuricemia. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of hyperuricemia drug candidates.
The clinical study sponsored by Jiangsu HengRui Medicine Co., Ltd. aims to evaluate the efficacy and safety of HR091506 tablets in treating gout with hyperuricemia in adults. The Phase III study will compare HR091506 tablets with febuxostat tablets. The study is expected to be completed by June 2025, with approximately 750 participants enrolled.
The Phase II/III study, sponsored by Guangzhou Ruianbo Pharmaceutical Technology Co., Ltd, aims to evaluate the efficacy and safety of AR882 capsules in patients with primary gout and hyperuricemia. The study compares AR882 with Febuxostat tablets, focusing on serum uric acid reduction. It is expected to be completed by April 2026, with an estimated 636 participants.
Intelligem Therapeutics Australia Pty Ltd. is sponsoring a Phase I/II clinical study, that aims to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of IG3018 tablets in subjects with hyperuricemia, with or without chronic kidney disease (CKD). The study plans to enroll around 46 participants and is expected to be completed by January 2026.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Hyperuricemia Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for hyperuricemia. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into hyperuricemia collaborations, regulatory environments, and potential growth opportunities.
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share